5 research outputs found
Effects of GPR139 agonism on effort expenditure for food reward in rodent models: Evidence for pro-motivational actions
Apathy, deficiency of motivation including willingness to exert effort for reward, is a common symptom in many psychiatric and neurological disorders, including depression and schizophrenia. Despite improved understanding of the neurocircuitry and neurochemistry underlying normal and deficient motivation, there is still no approved pharmacological treatment for such a deficiency. GPR139 is an orphan G protein-coupled receptor expressed in brain regions which contribute to the neural circuitry that controls motivation including effortful responding for reward, typically sweet gustatory reward. The GPR139 agonist TAK-041 is currently under development for treatment of negative symptoms in schizophrenia which include apathy. To date, however, there are no published preclinical data regarding its potential effect on reward motivation or deficiencies thereof. Here we report in vitro evidence confirming that TAK-041 increases intracellular Ca2+ mobilization and has high selectivity for GPR139. In vivo, TAK-041 was brain penetrant and showed a favorable pharmacokinetic profile. It was without effect on extracellular dopamine concentration in the nucleus accumbens. In addition, TAK-041 did not alter the effort exerted to obtain sweet gustatory reward in rats that were moderately food deprived. By contrast, TAK-041 increased the effort exerted to obtain sweet gustatory reward in mice that were only minimally food deprived; furthermore, this effect of TAK-041 occurred both in control mice and in mice in which deficient effortful responding was induced by chronic social stress. Overall, this study provides preclinical evidence in support of GPR139 agonism as a molecular target mechanism for treatment of apathy
Muscle to Brain Partitioning as Measure of Transporter-Mediated Efflux at the Rat Blood–Brain Barrier and Its Implementation into Compound Optimization in Drug Discovery
Movement of xenobiotic substances across the blood–brain barrier (BBB) is tightly regulated by various transporter proteins, especially the efflux transporters P-glycoprotein (P-gp/MDR1) and breast cancer resistance protein (BCRP). Avoiding drug efflux at the BBB is a unique challenge for the development of new central nervous system (CNS) drugs. Drug efflux at the BBB is described by the partition coefficient of unbound drug between brain and plasma (Kp,uu,brain) which is typically obtained from in vivo and often additionally in vitro measurements. Here, we describe a new method for the rapid estimation of the in vivo drug efflux at the BBB of rats: the measurement of the partition coefficient of a drug between brain and skeletal muscle (Kp,brain/muscle). Assuming a closely similar distribution of drugs into the brain and muscle and that the efflux transporters are only expressed in the brain, Kp,brain/muscle, similar to Kp,uu,brain, reflects the efflux at the BBB. The new method requires a single in vivo experiment. For 64 compounds from different research programs, we show the comparability to other approaches used to obtain Kp,uu,brain. P-gp- and BCRP-overexpressing cell systems are valuable in vitro tools for prescreening. Drug efflux at the BBB can be most accurately predicted based on a simple algorithm incorporating data from both in vitro assays. In conclusion, the combined use of our new in vivo method and the in vitro tools allows an efficient screening method in drug discovery with respect to efflux at the BBB
A Bidirectional Permeability Assay for beyond Rule of 5 Compounds
Bidirectional permeability measurement with cellular models grown on Transwell inserts is widely used in pharmaceutical research since it not only provides information about the passive permeability of a drug, but also about transport proteins involved in the active transport of drug substances across physiological barriers. With the increasing number of investigative drugs coming from chemical space beyond Lipinski’s Rule of 5, it becomes more and more challenging to provide meaningful data with the standard permeability assay. This is exemplified here by the difficulties we encountered with the cyclic depsipeptides emodepside and its close analogs with molecular weight beyond 1000 daltons and cLogP beyond 5. The aim of this study is to identify potential reasons for these challenges and modify the permeability assays accordingly. With the modified assay, intrinsic permeability and in vitro efflux of depsipeptides could be measured reliably. The improved correlation to in vivo bioavailability and tissue distribution data indicated the usefulness of the modified permeability assay for the in vitro screening of compounds beyond the Rule of 5
Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P‑gp Substrates
Transporters at the blood-brain barrier
(BBB) and the blood-cerebrospinal
fluid barrier (BCSFB) play a pivotal role as gatekeepers for efflux
or uptake of endogenous and exogenous molecules. The protein expression
of a number of them has already been determined in the brains of rodents,
nonhuman primates, and humans using quantitative targeted absolute
proteomics (QTAP). The dog is an important animal model for drug discovery
and development, especially for safety evaluations. The purpose of
the present study was to clarify the relevance of the transporter
protein expression for drug distribution in the dog brain and CSF.
We used QTAP to examine the protein expression of 17 selected transporters
and receptors at the dog BBB and BCSFB. For the first time, we directly
linked the expression of two efflux transporters, P-glycoprotein (P-gp)
and breast cancer resistance protein (BCRP), to regional brain and
CSF distribution using specific substrates. Two cocktails, each containing
one P-gp substrate (quinidine or apafant) and one BCRP substrate (dantrolene
or daidzein) were infused intravenously prior to collection of the
brain. Transporter expression varied only slightly between the capillaries
of different brain regions and did not result in region-specific distribution
of the investigated substrates. There were, however, distinct differences
between brain capillaries and choroid plexus. Largest differences
were observed for BCRP and P-gp: both were highly expressed in brain
capillaries, but no BCRP and only low amounts of P-gp were detected
in the choroid plexus. <i>K</i><sub>p,uu,brain</sub> and <i>K</i><sub>p,uu,CSF</sub> of both P-gp substrates were indicative
of drug efflux. Also, <i>K</i><sub>p,uu,brain</sub> for
the BCRP substrates was low. In contrast, <i>K</i><sub>p,uu,CSF</sub> for both BCRP substrates was close to unity, resulting in <i>K</i><sub>p,uu,CSF</sub>/<i>K</i><sub>p,uu,brain</sub> ratios of 7 and 8, respectively. We conclude that the drug transporter
expression profiles differ between the BBB and BCSFB in dogs, that
there are species differences in the expression profiles, and that
CSF is not a suitable surrogate for unbound brain concentrations of
BCRP substrates in dogs